<DOC>
<DOCNO>EP-1124809</DOCNO> 
<TEXT>
<INVENTION-TITLE>
BENZOYLPYRIDAZINES
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P3500	A61K3150	A61P104	A61P4300	A61P300	A61P1106	A61P1900	C07D40100	A61K31501	C07D40112	A61P2500	A61P3118	A61P2900	A61P2900	A61P3702	A61P4300	A61P100	A61K31501	C07D23700	A61P900	A61P1100	A61P3708	A61P3100	A61P310	A61P910	A61P1908	A61K3150	A61P3500	A61P3700	A61P3706	A61P1902	A61P2500	C07D23704	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61K	A61P	A61P	A61P	A61P	A61P	C07D	A61K	C07D	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61K	C07D	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61K	A61P	A61P	A61P	A61P	A61P	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P35	A61K31	A61P1	A61P43	A61P3	A61P11	A61P19	C07D401	A61K31	C07D401	A61P25	A61P31	A61P29	A61P29	A61P37	A61P43	A61P1	A61K31	C07D237	A61P9	A61P11	A61P37	A61P31	A61P3	A61P9	A61P19	A61K31	A61P35	A61P37	A61P37	A61P19	A61P25	C07D237	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to benzoyl pyridazine derivatives of formula (I), wherein R
<
1
>
, R
<
2
>
, R
<
3
>
 and Q have the meaning defined in claim 1. Said derivatives have a phosphodiesterase IV inhibiting effect and can be used in the treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases and AIDS.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
MERCK PATENT GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
MERCK PATENT GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
JONAS ROCHUS
</INVENTOR-NAME>
<INVENTOR-NAME>
KLUXEN FRANZ-WERNER
</INVENTOR-NAME>
<INVENTOR-NAME>
WOLF MICHAEL
</INVENTOR-NAME>
<INVENTOR-NAME>
JONAS, ROCHUS
</INVENTOR-NAME>
<INVENTOR-NAME>
KLUXEN, FRANZ-WERNER
</INVENTOR-NAME>
<INVENTOR-NAME>
WOLF, MICHAEL
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Compounds of the formula I


in which

R
1
, R
2
in each case independently of one another are
-OH, OR
5
, -S-R
5
, -SO-R
5
, -SO
2
-R
5
 or Hal,
R
1
 and R
2
together are also -O-CH
2
-O-,
R
3
is NH
2
, NHa, NAA' or a saturated heterocycle
having 1 to 4 N, O and/or S atoms which can

be unsubstituted or mono-, di- or trisubstituted
by Hal, A and/or OA,
Q
is absent or is branched or unbranched
alkylene having 1-10 C atoms,
R
5
is A, cycloalkyl having 3-7 C atoms,
alkylenecycloalkyl having 4-8 C atoms or

alkenyl having 2-8 C atoms,
A, A'
in each case independently of one another are
alkyl which has 1 to 10 C atoms and which can

be substituted by 1 to 5 F and/or Cl atoms
and
Hal
is F, Cl, Br or I,
 
and the physiologically acceptable salts and solvates

thereof.
Compounds of the formula I according to Claim 1

(a) 3-dimethylaminopropyl {4-[3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl]-phenyl}carbamate;
(b) N-methylpiperidin-4-yl-{4-[3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl]-phenyl}carbamate;
(c) 3-dimethylaminopropyl {4-[3-(3-isopropoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate;
(d) 3-dimethylaminopropyl {3-[3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl]-phenyl}carbamate;

and the physiologically acceptable salts and solvates
thereof.
Process for the preparation of compounds of the
formula I according to Claim 1 and salts thereof,


characterized in that
 a compound of the formula II


in which

R
1
 and R
2
 have the meanings given in Claim 1

is reacted with a compound of the formula III


in which

Q and R
3
have the meanings given in Claim 1 and 
L
is Cl, Br, OH or a reactive esterified OH
group,

or
in that
 a compound of the formula IV


in which

R
1
 and R
2
 have the abovementioned meanings

is reacted with a compound of the formula V

R
3
-Q-O-CO-L

in which

R
3
 and Q
have the abovementioned meanings and
L
is Cl, Br, OH or a reactive esterified OH group,

and/or 
in that
 a basic compound of the formula I is
converted into a salt thereof by treatment with an

acid.
Process for the preparation of pharmaceutical
products, 
characterized in that
 a compound of the
formula I according to Claim 1 and/or a physiologically

acceptable salt thereof is brought into a suitable
pharmaceutical form together with at least one solid,

liquid or semi-liquid excipient or auxiliary.
Pharmaceutical product, 
characterized in that

it comprises at least one compound of the formula I
according to Claim 1 and/or a physiologically

acceptable salt thereof.
Compounds of the formula I according to Claim 1
and the physiologically acceptable salts thereof for

combating osteoporosis, tumours, cachexia,
atherosclerosis, rheumatoid arthritis, multiple

sclerosis, diabetes mellitus, ulcerative colitis,
inflammatory diseases, allergies, asthma, autoimmune

diseases, AIDS and transplant rejection reactions. 
Pharmaceuticals of the formula I according to
Claim 1 and the physiologically acceptable salts

thereof as phosphodiesterase IV inhibitors.
Use of compounds of the formula I according to
Claim 1 an
d/or of the physiologically acceptable salts
thereof for the preparation of a pharmaceutical.
Compounds of the formula I according to Claim 1
and/or of the physiologically acceptable salts thereof

for use for combating diseases.
</CLAIMS>
</TEXT>
</DOC>
